Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17456561 | 0.98 | LMNA (0.52) | LMNAPPARGACHEHTTTDP1 | |
| SCHEMBL9664445 | 0.85 | CA1 (0.60) | PPARGCA1CA2CA9ALDH1A1 | |
| SCHEMBL3884174 | 0.83 | ACHE (0.56) | LMNAPPARGACHEHTTTDP1 | |
| SCHEMBL29468643 | 0.83 | ACHE (0.56) | LMNAPPARGACHEHTTTDP1 | |
| SCHEMBL4599461 | 0.82 | PPARG (0.58) | LMNAPPARGACHEHTTTDP1 | |
| SCHEMBL9451450 | 0.80 | CA2 (0.73) | PPARGACHECA1CA2CA9 | |
| SCHEMBL11164410 | 0.80 | PPARG (0.53) | LMNAPPARGACHEHTTTDP1 | |
| SCHEMBL14015386 | 0.80 | STS (0.54) | LMNAACHEHTTTDP1L3MBTL1 | |
| SCHEMBL19568043 | 0.80 | PPARG (0.53) | LMNAPPARGACHEHTTTDP1 | |
| SCHEMBL4138555 | 0.79 | HTT (0.61) | LMNAPPARGHTTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126189-A | 3-thio-3- (trimethylsilyl) -1-ketone compound, preparation method and application thereof | 南京工业大学 | 2023-11-28 | — | — | CN | claimed |
| CN-119684180-A | Method for synthesizing thio-ester compound | 南通大学 | 2025-03-25 | — | — | CN | disclosed |
| US-12259397-B2 | Biomarkers related to organ function | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250024837-A1 | PESTICIDE SYSTEM | BANISH, MICHELE | 2025-01-23 | — | — | US | disclosed |
| CN-117126189-A | 3-thio-3- (trimethylsilyl) -1-ketone compound, preparation method and application thereof | 南京工业大学 | 2023-11-28 | — | — | CN | disclosed |
| CN-116947719-A | Synthesis method of visible light two-dimensional alkene nanomaterial synergistic catalysis disulfide compound | 南通大学 | 2023-10-27 | — | — | CN | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3186245-B1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2021-06-23 | — | — | EP | disclosed |
| CN-107074831-B | MAPK inhibitors | 永辉药业 | 2020-12-08 | — | — | CN | disclosed |
| US-20200284805-A1 | BIOMARKERS RELATED TO ORGAN FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-09-10 | — | — | US | disclosed |
| US-20110257430-A1 | NOVEL COCRYSTALLIZATION | APTUIT (KANSAS CITY), LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110251426-A1 | SCREENING FOR SOLID FORMS BY ULTRASOUND CRYSTALLIZATION AND COCRYSTALLIZATION USING ULTRASOUND | S.S.C.I., INC. (US) | 2011-10-13 | — | — | US | disclosed |
| EP-2292585-A1 | Screening for solid forms by ultrasound crystallization and cocrystallization using ultrasound | APTUIT (KANSAS CITY), LLC (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20090281195-A1 | NOVEL COCRYSTALLIZATION | S.S.C.I., INC. (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-7452555-B2 | Cocrystallization | S.S.C.I., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070287194-A1 | Screening For Solid Forms By Ultrasound Crystallization And Cocrystallization Using Ultrasound | S.S.C.I., INC | 2007-12-13 | — | — | US | disclosed |
| US-20070088508-A1 | Cocrystallization methods | APTUIT (WEST LAFAYETTE), LLC | 2007-04-19 | — | — | US | disclosed |
| US-6284473-B1 | P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status | UAB RESEARCH FOUNDATION | 2001-09-04 | — | — | US | disclosed |
| WO-2001025787-A1 | p-CRESOL SULFATE, A COMPONENT OF URINARY MYELIN BASIC PROTEIN-LIKE MATERIAL, AS A CORRELATE OF MULTIPLE SCLEROSIS STATUS | UAB RESEARCH FOUNDATION (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250024837-A1 | PESTICIDE SYSTEM | ACHE, PFAS, FPGS | LMNA 3099/4885PPARG 836/4885ACHE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.